fbpx

Nyheder

Lundbeckfonden Ventures nyheder

SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis SNF472 treated patients had coronary artery calcium (CAC) volume score progression of 11% from baseline versus 20% in patients receiving placebo (P=0.016) SNF472 was well tolerated Results are remarkable as they have been achieved in patients who continued to...
Monday 18 November at 11:00 ET /16:00 GMT / 17:00 CET Sanifit will host a webcast on Monday November 18 at 11am ET / 5pm CET / 4pm GMT on the results of the international Phase 2b CaLIPSO study of lead candidate SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis. Joan Perelló, CEO and Alexander M....
Lund, Sweden, 7 November 2019 08.00 am CET, – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids, today publishes the interim report for the third quarter 2019. BONESUPPORT’S BEST QUARTER EVER “Sales in the quarter are our highest ever, with strong growth in both Europe and the US....
Lund, Sweden, 12:00 pm CET, 31 October 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids. During October, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased with 8,125 due to the exercise of warrants. As of 31 October 2019, the number of...
Cambridge, UK and Indianapolis, US – 30 October 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 940,442 Ordinary Shares of...
Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has met its primary endpoint. The study demonstrated a reduction in coronary...
Lund, Sweden, 08.00 am CET, 30 October 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids, will publish its Q3 2019 interim report on the 7 November 2019 at 08.00 am CET. The Company will hold a conference call and an online presentation on the same day...
Cambridge, UK and Indianapolis, US – 21 October 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 9,000 Ordinary Shares of...
Cambridge, UK and Indianapolis, US – 1 October 2019: Acacia Pharma Group plc (the “Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission in aggregate of 303,841 Ordinary Shares...
1 3 4 5 6 7 65

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
8. maj 2020
Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
7. maj 2020
Acacia Pharma Group PLC – Alessandro Della Chà appointed as Director of Acacia Pharma Group plc
9. april 2020